Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities
Medtronic (NYSE:MDT) has announced significant governance changes and strategic initiatives aimed at enhancing shareholder value. The company has appointed two new independent directors to its Board: John Groetelaars and Bill Jellison, both bringing extensive medical technology industry experience.
The Board has established two new special committees: a Growth Committee focusing on M&A, R&D investments, and potential divestitures (including the planned Diabetes business separation), and an Operating Committee dedicated to optimizing operational performance and margin expansion. These initiatives follow constructive engagement with Elliott Investment Management, one of Medtronic's largest investors.
The company plans to host an Investor Day in mid-2026 to discuss strategic priorities and financial objectives.
Medtronic (NYSE:MDT) ha annunciato importanti cambiamenti nella governance e nuove iniziative strategiche volte ad aumentare il valore per gli azionisti. Il Consiglio ha nominato due nuovi amministratori indipendenti, John Groetelaars e Bill Jellison, entrambi con una consolidata esperienza nel settore della tecnologia medica.
Sono stati creati due comitati speciali: il Growth Committee, focalizzato su fusioni e acquisizioni, investimenti in R&S e possibili disinvestimenti (compresa la prevista separazione del business Diabetes), e l’Operating Committee, dedicato all’ottimizzazione delle prestazioni operative e all’espansione dei margini. Queste mosse seguono un confronto costruttivo con Elliott Investment Management, uno dei maggiori investitori in Medtronic.
L’azienda ha inoltre annunciato l’intenzione di organizzare un Investor Day a metà 2026 per illustrare priorità strategiche e obiettivi finanziari.
Medtronic (NYSE:MDT) ha anunciado cambios relevantes en su gobierno corporativo y nuevas iniciativas estratégicas para mejorar el valor para los accionistas. La compañía ha incorporado a dos nuevos consejeros independientes, John Groetelaars y Bill Jellison, ambos con amplia experiencia en la industria de tecnología médica.
El Consejo ha creado dos comités especiales: un Growth Committee centrado en fusiones y adquisiciones, inversión en I+D y posibles desinversiones (incluida la prevista escisión del negocio de Diabetes), y un Operating Committee dedicado a optimizar el rendimiento operativo y ampliar los márgenes. Estas medidas siguen a un diálogo constructivo con Elliott Investment Management, uno de los mayores inversores de Medtronic.
La compañía también planea celebrar un Investor Day a mediados de 2026 para exponer prioridades estratégicas y objetivos financieros.
Medtronic (NYSE:MDT)는 주주 가치를 제고하기 위한 주요 거버넌스 변경과 전략적 이니셔티브를 발표했습니다. 회사는 의료기술 분야에서 풍부한 경력을 가진 두 명의 신규 사외이사 John Groetelaars와 Bill Jellison을 이사회에 선임했습니다.
이사회는 두 개의 특별위원회를 신설했습니다. 인수합병, 연구개발 투자 및 잠재적 자산매각(당사 당뇨병(=Diabetes) 사업 분리를 포함)을 담당하는 Growth Committee와 운영 성과 최적화 및 마진 확대에 전념하는 Operating Committee입니다. 이러한 조치는 Medtronic의 주요 투자자 중 하나인 Elliott Investment Management와의 생산적인 협의에 따른 것입니다.
회사는 전략적 우선순위와 재무 목표를 논의하기 위해 2026년 중반 Investor Day를 개최할 계획입니다.
Medtronic (NYSE:MDT) a annoncé d’importantes évolutions de gouvernance et des initiatives stratégiques visant à accroître la valeur pour les actionnaires. La société a nommé deux nouveaux administrateurs indépendants, John Groetelaars et Bill Jellison, tous deux dotés d’une vaste expérience dans le secteur des technologies médicales.
Le conseil a créé deux comités spéciaux : un Growth Committee dédié aux fusions-acquisitions, aux investissements en R&D et aux éventuelles cessions (y compris la séparation prévue de l’activité Diabetes), et un Operating Committee chargé d’optimiser la performance opérationnelle et l’expansion des marges. Ces mesures font suite à des échanges constructifs avec Elliott Investment Management, l’un des principaux investisseurs de Medtronic.
La société prévoit par ailleurs d’organiser un Investor Day à la mi‑2026 pour présenter ses priorités stratégiques et ses objectifs financiers.
Medtronic (NYSE:MDT) hat bedeutende Änderungen in der Unternehmensführung sowie strategische Maßnahmen angekündigt, um den Aktionärswert zu steigern. Der Vorstand berief zwei neue unabhängige Direktoren, John Groetelaars und Bill Jellison, die beide über umfassende Erfahrungen in der Medizintechnikbranche verfügen.
Es wurden zwei neue Sonderausschüsse eingerichtet: ein Growth Committee, das sich auf M&A, F&E-Investitionen und mögliche Veräußerungen (einschließlich der geplanten Abspaltung des Diabetes-Geschäfts) konzentriert, und ein Operating Committee, das die operative Leistung und die Margenausweitung optimieren soll. Diese Schritte folgen auf einen konstruktiven Dialog mit Elliott Investment Management, einem der größten Investoren von Medtronic.
Das Unternehmen plant zudem, ein Investor Day Mitte 2026 abzuhalten, um strategische Prioritäten und finanzielle Ziele darzulegen.
- Addition of two highly experienced medical technology executives to the Board
- Formation of specialized committees to enhance strategic focus and operational efficiency
- Constructive engagement with major investor Elliott Management indicates strong institutional support
- Planned separation of Diabetes business to create more focused operations
- Multiple growth drivers already delivering results with additional breakthrough therapies pending launch
- Extended timeline for Investor Day presentation (mid-2026) may delay detailed strategic updates
- Operational restructuring and business separation could create short-term disruptions
Insights
Medtronic's board restructuring and new committees signal active value creation strategy after Elliott's involvement, positioning for operational improvements.
Medtronic's latest board appointments and governance changes represent a significant response to shareholder activism and signal a potential inflection point for the medical device giant. The addition of industry veterans John Groetelaars and Bill Jellison brings valuable operational and financial expertise that aligns perfectly with the company's renewed focus areas.
The formation of dedicated Growth and Operating committees is particularly noteworthy as it institutionalizes two critical priorities: portfolio optimization and operational efficiency. These committees provide formal board-level oversight for initiatives that were likely already underway at the management level, but now with enhanced accountability and visibility to investors.
Elliott Management's involvement as a major shareholder and their public endorsement of these changes is a critical element here. Elliott has a strong track record of pushing for transformative changes at healthcare companies, and their "strong conviction" statement suggests they see substantial unrealized value. Their constructive partnership approach, rather than a more combative stance, indicates Medtronic management has been responsive to their recommendations.
The planned Diabetes business separation mentioned in the release represents a concrete example of the portfolio rationalization that investors have been seeking. This divestiture would allow Medtronic to focus resources on higher-growth, higher-margin segments while potentially unlocking value in the separated business.
The announcement of an Investor Day in 2026 establishes a public milestone against which management's execution will be measured. This creates a timeline for accountability that will likely accelerate internal decision-making on strategic initiatives in the coming months. The company's reference to "breakthrough therapies set to launch in the months ahead" suggests the timing is deliberate to coincide with new product cycles that could drive growth.
Experienced executives John Groetelaars and Bill Jellison appointed to the Board of Directors
Board forms new Growth and Operating committees to sharpen focus on the company's ongoing strategic portfolio management, operational execution and capital allocation
Plan to host Investor Day in 2026
Initiatives follow constructive engagement with Elliott Management
GALWAY,
Consistent with the company's commitment to shareholder value creation, and to provide enhanced focus and urgency around Medtronic's ongoing strategic portfolio management, operational improvement and capital allocation, the Board has formed the following special committees to align our governance with existing management focus areas and workstreams:
- The Growth Committee will be responsible for guiding the evaluation and execution of growth-accretive tuck-in M&A, organic R&D investments, and potential divestitures, including the continued execution of the recently announced plan to separate its Diabetes business.
- The Operating Committee will align governance with the company's initiatives to optimize operational performance, deliver margin expansion, and drive sustained earnings acceleration, including actions company management is taking to improve efficiency in its global manufacturing, supply chain, and operations.
Chief Executive Officer and Chairman of the Board, Geoff Martha, will serve as Chair of both of the newly formed committees, and newly appointed directors, Groetelaars and Jellison, will also serve on one or both of the committees.
"I am pleased to welcome John and Bill to the Medtronic Board of Directors – each of whom brings decades of relevant experience delivering growth as executives and directors of public companies in the medical technology industry. John's leadership managing global operations and Bill's deep financial expertise will also be valuable to the boardroom," said Geoff Martha, chairman and chief executive officer. "We are at an exciting inflection point and in a period of strong momentum, with multiple growth drivers already delivering and additional breakthrough therapies set to launch in the months ahead. With the addition of these new Board members and the formation of these two new committees, we are accelerating our strategic growth priorities and advancing the simplification and optimization of our operations. The separation of MiniMed is an example of the important steps we're taking to create a more focused and more profitable Medtronic. By sharpening our focus on high-margin growth opportunities, we are well-positioned to deliver stronger performance and greater value for patients, customers, and shareholders."
Medtronic will host an Investor Day in mid-calendar year 2026 at which the company will discuss the work of the Growth Committee and Operating Committee, including Medtronic's go-forward strategic priorities and financial algorithm.
Today's initiatives follow constructive dialogue with Elliott Investment Management L.P. ("Elliott").
Martha continued, "We appreciate our productive dialogue with Marc Steinberg and the Elliott team. The durable growth drivers now taking hold across several of our businesses are strengthening Medtronic's trajectory and reinforcing our conviction in the company's future. The Board believes Medtronic has the right strategies to build on this momentum and deliver sustained, superior returns for investors over the long-term."
Elliott Partner Marc Steinberg said, "Our decision to become one of Medtronic's largest investors was driven by our strong conviction that the company is entering a new chapter of exceptional value creation defined by accelerating growth, operational improvement and enhanced strategic clarity. We believe Medtronic's recent innovations in some of the medical technology sector's most attractive markets have positioned the company for an inflection in organic growth. Combined with its renewed focus on portfolio simplification and improved operational execution, Medtronic is set to deliver a sustainable acceleration in earnings growth as well. Today's announcements – including the addition of new directors with deep medical technology experience and the formation of two focused Board committees – are the right steps towards realizing Medtronic's potential. We look forward to continuing our constructive partnership with Geoff Martha and the Board and to working closely together to realize this unique value-creation opportunity."
Groetelaars and Jellison will be nominated to stand for election to the Board at Medtronic's 2025 Annual General Meeting of Shareholders.
New Board Member Biographies
John Groetelaars brings more than 30 years of global leadership experience across a broad range of medical device sectors. Most recently, Groetelaars served as interim CEO for Dentsply Sirona, having previously served in a director role for the company. Prior to Dentsply Sirona, John was President & CEO at Hillrom from May 2018 until the company's acquisition by Baxter International, Inc. in 2021. At Hillrom, he provided global leadership for a healthcare technology company with
Currently, Groetelaars serves as Chairman of the Board of Directors for Zeus Industrial Products. He is also a Board member for Parexel, a global clinical research organization.
Groetelaars earned a bachelor's degree in Mechanical Engineering from Kettering University and an MBA from Columbia University.
William Jellison is a former medical technology executive and corporate finance expert. From 2013 to 2016, he served as the Vice President, Chief Financial Officer of Stryker Corporation, a global leader in medical technologies. Before joining Stryker, Jellison spent 15 years at Dentsply International in several leadership positions, including CFO. Jellison began his career with the Donnelly Corporation, holding multiple financial management and executive roles, including Vice President of Finance, Treasurer and Corporate Controller.
Jellison currently serves as a Senior Advisor for Astor Place Holdings, the Private Equity arm of Select Equities, and consults with other companies in the medical technology industry. He serves as a director of public companies Avient Corporation and Anika Therapeutics, Inc. as well as a director of private companies Solenis and Young Innovations.
Jellison received a B.A. in Business Administration from Hope College.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway,
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts:
Erika Winkels
Public Relations
+1-763-526-8478
Ryan Weispfenning
Investor Relations
+1-763-505-4626
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-board-appointments-and-shareholder-value-creation-initiatives-to-advance-strategic-priorities-302533027.html
SOURCE Medtronic plc
FAQ
Who are the new board members appointed to Medtronic (MDT)?
What are the two new committees formed by Medtronic's Board?
What is Elliott Investment Management's role in Medtronic's new initiatives?
When will Medtronic host its next Investor Day?
What is happening with Medtronic's Diabetes business?
